Global Sexually Transmitted Diseases (STDs) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sexually Transmitted Diseases (STDs) Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Sexually Transmitted Diseases (STDs) Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sexually Transmitted Diseases (STDs) Drug market is projected to reach US$ 39550 million in 2034, increasing from US$ 21030 million in 2022, with the CAGR of 9.0% during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Sexually Transmitted Diseases (STDs) Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Sexually Transmitted Diseases (STDs) Drug key manufacturers include Pfizer, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, AbbVie, Inc., Gilead Sciences and GlaxoSmithKline Plc, etc. Pfizer, Hoffmann La Roche, Bayer Healthcare are top 3 players and held % sales share in total in 2022.
Sexually Transmitted Diseases (STDs) Drug can be divided into Chlamydia, Gonorrhea, Syphilis and Genital herpes, etc. Chlamydia is the mainstream product in the market, accounting for % sales share globally in 2022.
Sexually Transmitted Diseases (STDs) Drug is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Sexually Transmitted Diseases (STDs) Drug industry development. In 2022, global % sales of Sexually Transmitted Diseases (STDs) Drug went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sexually Transmitted Diseases (STDs) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Hoffmann La Roche
Bayer Healthcare
Eli Lilly
Johnson & Johnson
Bristol-Myers Squibb
AbbVie, Inc.
Gilead Sciences
GlaxoSmithKline Plc
Merck & Co., Inc.
Segment by Type
Chlamydia
Gonorrhea
Syphilis
Genital herpes
HPV
HIV / AIDS
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sexually Transmitted Diseases (STDs) Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sexually Transmitted Diseases (STDs) Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sexually Transmitted Diseases (STDs) Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sexually Transmitted Diseases (STDs) Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sexually Transmitted Diseases (STDs) Drug introduction, etc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Sexually Transmitted Diseases (STDs) Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Sexually Transmitted Diseases (STDs) Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Sexually Transmitted Diseases (STDs) Drug key manufacturers include Pfizer, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, AbbVie, Inc., Gilead Sciences and GlaxoSmithKline Plc, etc. Pfizer, Hoffmann La Roche, Bayer Healthcare are top 3 players and held % sales share in total in 2022.
Sexually Transmitted Diseases (STDs) Drug can be divided into Chlamydia, Gonorrhea, Syphilis and Genital herpes, etc. Chlamydia is the mainstream product in the market, accounting for % sales share globally in 2022.
Sexually Transmitted Diseases (STDs) Drug is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Sexually Transmitted Diseases (STDs) Drug industry development. In 2022, global % sales of Sexually Transmitted Diseases (STDs) Drug went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sexually Transmitted Diseases (STDs) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Hoffmann La Roche
Bayer Healthcare
Eli Lilly
Johnson & Johnson
Bristol-Myers Squibb
AbbVie, Inc.
Gilead Sciences
GlaxoSmithKline Plc
Merck & Co., Inc.
Segment by Type
Chlamydia
Gonorrhea
Syphilis
Genital herpes
HPV
HIV / AIDS
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sexually Transmitted Diseases (STDs) Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sexually Transmitted Diseases (STDs) Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sexually Transmitted Diseases (STDs) Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sexually Transmitted Diseases (STDs) Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sexually Transmitted Diseases (STDs) Drug introduction, etc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Sexually Transmitted Diseases (STDs) Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices